Acquiring Company
argenx
Acquired Company
Unnatural Products
Amsterdam
Santa CruzBiotechnologyHealth CareTherapeuticsBiotechnologyDescription
argenx has agreed to acquire Unnatural Products for $550 million upfront plus contingent value rights, for up to about $1.15 billion in total. The deal builds on a two-year research collaboration, and UNP will continue operating from Santa Cruz. Closing is expected by year-end, subject to customary closing conditions, so the deal has not yet completed.
Who to call at argenx, and when
When argenx changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day argenx raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at argenx, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at argenx. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment argenx makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Unnatural Products?
Unnatural Products was acquired by argenx, based in Amsterdam. The deal was reported on November 9, 2026. argenx is a global immunology innovation company focused on developing therapies for patients with severe autoimmune diseases. argenx is publicly traded (ARGX) and operates in Biotechnology.
When did argenx acquire Unnatural Products?
argenx's acquisition of Unnatural Products was reported on November 9, 2026. argenx has agreed to acquire Unnatural Products for $550 million upfront plus contingent value rights, for up to about $1.15 billion in total. The deal builds on a two-year research collaboration, and UNP will continue operating from Santa Cruz. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Unnatural Products do?
Unnatural Products, Inc. (UNP), a California biotech company, has developed a platform that addresses the complexities of medicinal chemistry in the macrocycle space through a combination of parallel experimentation and machine learning. It is privately held, operating in Biotechnology, and is based in Santa Cruz.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.